Pharma Outsourcing - The Online Scientific Community

Permission to use, copy and distribute documents presented on this World Wide Web site and related graphics is not granted without prior written permission of Technology Networks Ltd

To obtain this permission contact:
Technology Networks Ltd
Unit 6, Woodview
Bull Lane
Acton
Sudbury
CO10 0FD, U.K.

In cases where permission is granted, it is done so under the provision that the above copyright notice and this permission notice appear in all copies. All other rights are reserved.

The information and data included in the TechnologyNetworks.com WWW site, and all its affiliated websites and associated email newsletters, have been compiled from a variety of sources, and are subject to change without notice. Technology Networks Ltd. makes no warranties or representations whatsoever regarding the quality, content, completeness, or adequacy of this information and data.

Technology Networks Ltd. specifically disclaims all warranties with respect to this WWW site, email newsletters or your use thereof, express, implied, or otherwise, including without limitation, all warranties of merchantability and fitness for a particular purpose. Technology Networks Ltd shall not be liable for any special, incidental, or consequential damages, including, without limitation, lost revenues, lost profits, or loss of prospective economic advantage, resulting from the use or misuse of this site, or the information therein.

Big Multiple Sclerosis Breakthrough
Phase 1 trial safely resets patients’ immune systems, reduces attack on myelin protein.

Combined Immunotherapy Shows Promising Results Against Advanced Melanoma
Combining two cancer immunotherapy drugs in patients with advanced melanoma produced rates of tumor regression that appeared greater than in prior trials with either drug alone.

NIH to Fund Clinical Research Network on Antibacterial Resistance
Researchers at Duke University will lead the initiative.

Combined Immunotherapy Shows Promising Results Against Advanced Melanoma
Tumor regression rates are produced by combining two cancer immunotherapy drugs.

Promising Drug Prevents Cancer Cells from Shutting Down Immune System
Data from Phase 1 trial presented at the 2013 annual meeting of the ASCO in Chicago.

Double Dose of Tamiflu Offers No Added Benefit in Severe Flu
Early treatment with Tamiflu is beneficial for patients with uncomplicated flu infection.

Enzyme-Activating Antibodies Revealed As Marker for Severe Rheumatoid Arthritis
Finding could lead to earlier diagnosis and new, more aggressive treatment for worst cases.

Researchers Identify Novel Class of Drugs for Prostate Cancers
A new study on prostate cancer describes a novel class of drugs that interrupts critical signaling needed for prostate cancer cells to grow.

Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Collaborate
Partnership will accelerate the pace of discovery and innovation in Biomedical Sciences.

First Patient Dosed in the Phase I/II Study of UC1010 for PMDD Patients
First patient has been dosed with UC1010 in a double-blind, multicenter study.